Rognostication. 37. Yurdaydin C. Therapy of chronic delta hepatitis. Semin Liver Dis.

Rognostication. 37. Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:2374. 38. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22:2272. 39. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin therapy for chronic hepatitis D: a pilot study. Liver. 1994;14:154. 40. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir therapy of chronic delta hepatitis. J Hepatol. 2002;37:2661. 41. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology. 1999;30:546. 42. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:3221. 43. Heidrich B, Manns MP, Wedemeyer H. Treatment selections for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15:31. 44. Heidrich B, Yurdaydin C, Kabacam G, et al. Long-term followup soon after Peg-IFNa2a-based therapy of chronic hepatitis delta. J Hepatol. 2013;58:S20. This paper is very critical as a result of the final data displaying only a 15 long-term cure price for HDV , whereas historically there had been publications that proposed remedy rates of 30 or higher The study delivers clear evidence that . we want new targeted therapies for HDV. 45. Farci P, Mandas A, Coiana A, et al. Therapy of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:884. 46. Lamers MH, Kirgiz OO, Heidrich B, et al. Interferon-alpha for patients with chronic hepatitis delta: a systematic critique of randomized clinical trials. Antivir Ther. 2012;17:10297. 47. Alavian SM, Tabatabaei SV, Behnava B, et al. Common and pegylated interferon therapy of HDV infection: a systematic evaluation and meta- analysis.Ruxolitinib J Res Med Sci.Eplerenone 2012;17:9674.PMID:23865629 48. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in mixture with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:7130. 49. Ormeci N, Bolukbas F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. 2011;58:16483. 50. Kabacam G, Dalekos GN, Cakaloglu Y, et al. Pegylated interferonbased therapy in patients with sophisticated liver disease resulting from chronic delta hepatitis. Turk J Gastroenterol. 2012;23:560. 51.Curr Gastroenterol Rep (2014) 16:365 Sanchez-Tapias JM, Mas A, Costa J, et al. Recombinant alpha 2cinterferon therapy in fulminant viral hepatitis. J Hepatol. 1987;five: 2050. 52. Heller T, Hoofnagle JH. Denying the wolf access to sheep’s clothing. J Clin Invest. 2003;112:3191. 53. Glenn JS, Watson JA, Havel CM, et al. Identification of a prenylation web-site in delta virus large antigen. Science. 1992;256: 1331. 54. Lutgehetmann M, Mancke LV, Volz T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:6854. 55. Mahtab MA, Bazinet M, Vaillant A. REP 9 AC: a potent HBsAg release inhibitor which will rapidly restore immunocompetence in sufferers with chronic hepatitis B. Hepatology. 2010;52:559A0. 56. Mahtab MA, Bazinet M, Vaillant A. REP 9AC: a potent HBsAg release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B. The 61st Annual Meeting of the American Association for the Study of Liver Ailments; Boston, Massachusetts; Oct 29-Nov two, 2010. 57. Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi th.